These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 8532697)
1. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Dabbs DJ Mod Pathol; 1995 Aug; 8(6):637-42. PubMed ID: 8532697 [TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices. Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161 [TBL] [Abstract][Full Text] [Related]
5. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
6. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices. Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387 [TBL] [Abstract][Full Text] [Related]
8. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641 [TBL] [Abstract][Full Text] [Related]
9. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508 [TBL] [Abstract][Full Text] [Related]
10. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
11. Comparison of proliferation activity in breast carcinoma by flow cytometry analysis of S-phase and quantitative analysis of MIB-1. Masood S; Bui MM; Lu L Ann Clin Lab Sci; 1998; 28(6):315-23. PubMed ID: 9846198 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671 [TBL] [Abstract][Full Text] [Related]
13. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion. Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of biomarkers in breast and prostate cancer. Grizzle WE; Myers RB; Arnold MM; Srivastava S J Cell Biochem Suppl; 1994; 19():259-66. PubMed ID: 7823598 [TBL] [Abstract][Full Text] [Related]
15. Identification of a basal-like subtype of breast ductal carcinoma in situ. Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468 [TBL] [Abstract][Full Text] [Related]
16. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Coltrera MD; Wang J; Porter PL; Gown AM Cancer Res; 1995 Jun; 55(12):2703-8. PubMed ID: 7780988 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunohistochemical staining for proliferating cell nuclear antigen, p53, and c-erbB-2 in sebaceous gland carcinoma and sweat gland carcinoma: comparison with histopathological parameter. Hasebe T; Mukai K; Yamaguchi N; Ishihara K; Kaneko A; Takasaki Y; Shimosato Y Mod Pathol; 1994 Jan; 7(1):37-43. PubMed ID: 7909154 [TBL] [Abstract][Full Text] [Related]
18. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients. Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885 [TBL] [Abstract][Full Text] [Related]
19. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366 [TBL] [Abstract][Full Text] [Related]
20. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases. Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]